BURLINGTON, Mass., May 07, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that
David Arkowitz has been named Chief Financial Officer (CFO). Mr. Arkowitz brings more than 25 years of finance and operations
leadership experience in the life sciences and biotechnology industries.
“I am delighted to have David come on board at such an important point in the company’s evolution,” said Michael Clayman, M.D.,
President and Chief Executive Officer of Flexion. “David has impeccable credentials, bringing deep business acumen, outstanding
leadership skills and broad commercial experience to this key role. I am confident that he will factor centrally in our future
success, and we are very fortunate to have him join us.”
“Flexion is a remarkable company with impressive leadership, a disruptive flagship product and promising growth potential,” said
Mr. Arkowitz. “I am honored and excited to be joining the team at this pivotal time, and I look forward to bringing my skills to
bear to achieve great things for patients, our employees and shareholders.”
Prior to joining Flexion, Mr. Arkowitz served as Chief Operating Officer and CFO at Visterra, Inc., where he led the finance,
business development, corporate planning, and other functions. Since 2014, Mr. Arkowitz has also served on the board of directors
and as chair of the audit committee of Spring Bank Pharmaceuticals, Inc., a public biopharmaceutical company. Previously Mr.
Arkowitz was CFO at Mascoma Corporation, AMAG Pharmaceuticals and Idenix Pharmaceuticals and held additional leadership positions
within each company. Preceding his tenure at Idenix, Mr. Arkowitz spent more than 13 years at Merck & Co., Inc. where he held roles
of increasing responsibility, including Vice President and Controller of the U.S. operations, Controller of the global research and
development division, and CFO of the Canadian subsidiary. He obtained his Bachelor’s degree in mathematics at Brandeis University
and his MBA in finance at Columbia University Business School.
Mr. Arkowitz succeeds Frederick Driscoll, who has been serving as the company’s financial advisor since announcing his
retirement in early 2017.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local
therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative
arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. For the past two years, Flexion has been
named one of the Best Places to Work by the Boston Business Journal, and Flexion was also recognized as a Top Place
to Work in Massachusetts by The Boston Globe in 2017.
Forward-Looking Statements
This release contains forward-looking statements that are based on the current expectations and beliefs of Flexion. Statements in
this press release regarding matters that are not historical facts, including, but not limited to, statements relating to the
future of Flexion and expected benefits of Flexion’s appointment of Mr. Arkowitz as CFO are forward-looking statements. These
forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are
subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied
by such statements. These risks and uncertainties include, without limitation, whether we are able to retain key employees
including Mr. Arkowitz; our ability to meet our goals; and other risks and uncertainties described in our filings with the
Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in our Annual Report on Form 10-K for the year
ended December 31, 2017 filed with the SEC on March 8, 2018 and subsequent filings with the SEC. The forward-looking statements in
this press release speak only as of the date of this press release, and we undertake no obligation to update or revise any of the
statements. We caution investors not to place considerable reliance on the forward-looking statements contained in this press
release.
Contact:
Scott
Young
Vice President, Corporate Communications & Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
syoung@flexiontherapeutics.com
A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/e41e249f-5e11-44c3-84cd-0c79e3d91c87
